Potent Inhibitors of Hepatitis C Core Dimerization As New Leads for Anti-hepatitis C Agents

Overview

Journal Bioorg Med Chem Lett

Specialty Biochemistry

Date 2011 Mar 29

PMID 21440437

Citations 10

Authors

Feng Ni

Smitha Kota

Virginia Takahashi

A Donny Strosberg

John K Snyder

Affiliations

Soon will be listed here.

Abstract

New indoline alkaloid-type compounds which inhibit HCV production by infected hepatoma cells have been identified. These compounds, dimeric-type compounds of previously known inhibitors, display double digit nanomolar IC(50) and EC(50) values, with cytotoxicity CC(50) indexes higher than 36 μM, thus providing ample therapeutic windows for further development of HCV drugs.

Citing Articles

Hepatitis C virus core protein: Not just a nucleocapsid building block, but an immunity and inflammation modulator.

Mani H, Yen J, Hsu H, Chang C, Liou J Tzu Chi Med J. 2022; 34(2):139-147.

PMID: 35465281 PMC: 9020238. DOI: 10.4103/tcmj.tcmj_97_21.

Targeting the Virus Capsid as a Tool to Fight RNA Viruses.

Hozakova L, Vokata B, Ruml T, Ulbrich P Viruses. 2022; 14(2).

PMID: 35215767 PMC: 8879806. DOI: 10.3390/v14020174.

Double the Chemistry, Double the Fun: Structural Diversity and Biological Activity of Marine-Derived Diketopiperazine Dimers.

Gomes N, Pereira R, Andrade P, Valentao P Mar Drugs. 2019; 17(10).

PMID: 31569621 PMC: 6835637. DOI: 10.3390/md17100551.

Chronic Hepatitis C Infection in Children: Current Treatment and New Therapies.

Lee A, Rajanayagam J, Abdel-Hady M J Clin Transl Hepatol. 2015; 3(1):36-41.

PMID: 26357633 PMC: 4542086. DOI: 10.14218/JCTH.2014.00036.

HCV core protein and virus assembly: what we know without structures.

Gawlik K, Gallay P Immunol Res. 2014; 60(1):1-10.

PMID: 24557493 PMC: 6659715. DOI: 10.1007/s12026-014-8494-3.

References

Rosenberg S . Recent advances in the molecular biology of hepatitis C virus. J Mol Biol. 2001; 313(3):451-64. DOI: 10.1006/jmbi.2001.5055. View

Melchiorre C, Andrisano V, Bolognesi M, Budriesi R, Cavalli A, Cavrini V . Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J Med Chem. 1998; 41(22):4186-9. DOI: 10.1021/jm9810452. View

Ruebsam F, Tran C, Li L, Kim S, Xiang A, Zhou Y . 5,6-Dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase. Bioorg Med Chem Lett. 2008; 19(2):451-8. DOI: 10.1016/j.bmcl.2008.11.048. View

Hadden M, Blagg B . Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells. Bioorg Med Chem Lett. 2007; 17(18):5063-7. PMC: 2682424. DOI: 10.1016/j.bmcl.2007.07.014. View

Pagliaccetti N, Robek M . Interferon-λ in HCV Infection and Therapy. Viruses. 2011; 2(8):1589-1602. PMC: 3185739. DOI: 10.3390/v2081589. View

Strosberg A, Kota S, Takahashi V, Snyder J, Mousseau G . Core as a novel viral target for hepatitis C drugs. Viruses. 2011; 2(8):1734-1751. PMC: 3185734. DOI: 10.3390/v2081734. View

Gestwicki J, Marinec P . Chemical control over protein-protein interactions: beyond inhibitors. Comb Chem High Throughput Screen. 2007; 10(8):667-75. DOI: 10.2174/138620707782507296. View

Burton Jr J, Everson G . HCV NS5B polymerase inhibitors. Clin Liver Dis. 2009; 13(3):453-65. DOI: 10.1016/j.cld.2009.05.001. View

Cavalli A, Bolognesi M, Capsoni S, Andrisano V, Bartolini M, Margotti E . A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew Chem Int Ed Engl. 2007; 46(20):3689-92. DOI: 10.1002/anie.200700256. View

10.

Appukkuttan P, Dehaen W, Fokin V, Van der Eycken E . A microwave-assisted click chemistry synthesis of 1,4-disubstituted 1,2,3-triazoles via a copper(I)-catalyzed three-component reaction. Org Lett. 2004; 6(23):4223-5. DOI: 10.1021/ol048341v. View

11.

Kota S, Scampavia L, Spicer T, Beeler A, Takahashi V, Snyder J . A time-resolved fluorescence-resonance energy transfer assay for identifying inhibitors of hepatitis C virus core dimerization. Assay Drug Dev Technol. 2009; 8(1):96-105. PMC: 2971647. DOI: 10.1089/adt.2009.0217. View

12.

Courcambeck J, Bouzidi M, Perbost R, Jouirou B, Amrani N, Cacoub P . Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Antivir Ther. 2007; 11(7):847-55. View

13.

Cholody W, Hernandez L, Hassner L, Scudiero D, Djurickovic D, Michejda C . Bisimidazoacridones and related compounds: new antineoplastic agents with high selectivity against colon tumors. J Med Chem. 1995; 38(16):3043-52. DOI: 10.1021/jm00016a007. View

14.

Kolb H, Finn M, Sharpless K . Click Chemistry: Diverse Chemical Function from a Few Good Reactions. Angew Chem Int Ed Engl. 2001; 40(11):2004-2021. DOI: 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5. View

15.

Simmonds P . Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004; 85(Pt 11):3173-3188. DOI: 10.1099/vir.0.80401-0. View

16.

Wei W, Cai C, Kota S, Takahashi V, Ni F, Strosberg A . New small molecule inhibitors of hepatitis C virus. Bioorg Med Chem Lett. 2009; 19(24):6926-30. PMC: 2783740. DOI: 10.1016/j.bmcl.2009.10.070. View

17.

Wang P, Chun B, Rachakonda S, Du J, Khan N, Shi J . An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase. J Org Chem. 2009; 74(17):6819-24. DOI: 10.1021/jo901345j. View

18.

Arkin M, Wells J . Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004; 3(4):301-17. DOI: 10.1038/nrd1343. View

19.

Chary A, Holodniy M . Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials. Rev Recent Clin Trials. 2010; 5(3):158-73. DOI: 10.2174/157488710792007293. View

20.

Blazer L, Neubig R . Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles. Neuropsychopharmacology. 2008; 34(1):126-41. DOI: 10.1038/npp.2008.151. View